The Veterinary Antibiotics Market Size is valued at 4794.0 Million in 2022 and is predicted to reach 6315.2 Million by the year 2031 at a 3.2 % CAGR during the forecast period for 2023-2031.
Antibiotics can be used to treat a single animal with clinical disease or a large group of animals. In many countries, antibiotics are commonly added to commercial feed for growth promotion in chickens. Antibiotics have effectively improved the rate and efficiency of gain in swine, cattle, and poultry. The different applications of antibiotics in food animals have been described as therapeutic use, prophylactic use, and subtherapeutic use. The global Veterinary antibiotics market is driven by end-use verticals consisting of dairy, meat industry applications. The increasing consumer preference for various dairy products and the rise in companion animal ownership is expected to increase the demand. Increasing animal disease outbreaks and increasing initiatives concerning animal health and welfare is anticipated to further strengthen its demand over the forecast period.
Market Segmentation
The Global Veterinary Antibiotics market is categorized on the basis of Product Type, Mode Of Delivery, Animal Type, and region. On the basis of Product Type, the market is segmented into Tetracyclines, Penicillins, Sulfonamides, Macrolides, Aminoglycosides, Lincosamides, Fluoroquinolones, Other Antimicrobials and Antibiotics. Based on Mode of delivery, the market is segmented into Premixes, Oral Powder, Oral Solution, Injection, and Others. Whereas Animal type segment includes Food-Producing Animals (Cattle, Pigs, Poultry, Sheep and Goats, Other Food-producing Animals) and Companion Animals (Dogs, Cats, Horses, Other Companion Animals). Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. On the other hand, North America is expected to dominate the market during the analysis of the forecast period.
Competitive Landscape
Some of The Key Players in The Veterinary Antibiotics Market:
- Bayer AG
- Boehringer Ingelheim GmbH
- Ceva Sante Animale S.A.
- Crystal Pharma
- Dechra Pharmaceuticals PLC
- Huvepharma AD
- Eli Lilly Company
- Elanco
- Merck & Co., Inc.
- Sanofi S.A.
- Vetoquinol S.A.
- Virbac
- Zoetis, Inc.
- Inovet Group
- Dopharma
- Other Prominent Players
The Veterinary Antibiotics Market Report Scope
Report Attribute |
Specifications |
Market Size Value In 2022 |
USD 4794.0 Million |
Revenue Forecast In 2031 |
USD 6315.2 Million |
Growth Rate CAGR |
CAGR of 3.2 % from 2023 to 2031 |
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
Historic Year |
2019 to 2022 |
Forecast Year |
2023-2031 |
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
Segments Covered |
By Product Type, By Mode Of Delivery, By Animal Type |
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
Competitive Landscape |
Bayer AG, Boehringer Ingelheim GmbH, Ceva Sante Animale S.A., Crystal Pharma, Dechra Pharmaceuticals PLC, Huvepharma AD, Eli Lilly Company, Elanco, Merck & Co., Inc., Sanofi S.A., Vetoquinol S.A., Virbac, Zoetis, Inc., Inovet Group, Dopharma, and Others |
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |